FOI release

Retatrutide

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/00164

Received 15 February 2026

Published 8 May 2026

Request

Under the UK Freedom of Information Act 2000, I am writing to request information held by the MHRA regarding the drug retatrutide. Specifically, I would like to request: 1. Any records of clinical trial approvals for retatrutide in the UK, including trial identifiers and statuses/timeframe of when clinical trials will finish 2. Any regulatory correspondence, safety assessments, or inspection reports related to retatrutide submitted to or reviewed by the MHRA. 3. Any releasable documents on projected timelines for clinical trial completion, regulatory review, or potential marketing authorisation. 4. Any MHRA-held data summarising adverse events, safety signals, or efficacy results submitted as part of UK clinical trials or post-market monitoring if applicable. (UK ONLY) 5. Any email communications held by the MHRA regarding the drug retatrutide between the agency and Eli Lilly or any other parties, including those relating to clinical trial applications, safety assessments, or regulatory approvals. I request that these emails, or non-exempt portions thereof, be released

Response

See attached

Documents

• FOI2026_00164 (redacted).pdf (1.2 MB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.